openPR Logo
Press release

Global Orphan Drug Pipeline & Regulatory Insight 2025

12-20-2018 01:09 PM CET | Health & Medicine

Press release from: PNS Pharma

” Global Orphan Drug Pipeline & Regulatory Insight 2025″ Report Highlights:

Global Orphan Drug Market Overview: US$ 260 Billion Opportunity
Global Orphan Drug market by Segment
Regulatory Landscape: USA, Europe & Asia
Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia
Global Orphan Drug Clinical Pipeline Insight: 973 Drugs
Marketed Orphan Drug Clinical Insight: 366 Drugs


Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Orphan-Drug-Pipeline-%26-Regulatory-Insight-2025



Orphan Drugs: Regimens For Rare Diseases


Drivers of Orphan Drug Commercialization
2.1 Cost Aspects

2.2 Expiration of Patented Drugs

2.3 Economic & Non-Economic Incentives

2.4 Advantage of Patent & Market Exclusivity

2.5 High Investment in Research & Development



Global Orphan Drug Market Perspectives: Current Market Evaluations


Global Orphan Drug Market by Segmentation
4.1 Market by Class Variation

4.2 Market by Therapeutic Application

4.3 Market by Regions



Global Orphan Drug Clinical Pipeline Overview


Global Orphan Drug Designation Criteria
6.1 US

6.2 Europe

6.3 Asia & Australia

6.3.1 Japan

6.3.2 Taiwan

6.3.3 South Korea

6.3.4 Australia



Global Orphan Drug Reimbursement Policy
7.1 US

7.2 Europe

7.3 Asia



FDA Regulation for Clinical Trials Orphan Designated Drugs
8.1 Content & Format Of A Request For Written Recommendations

8.2 Provision For Granting & Refusing Written Recommendations

8.3 Content And Format Of A Request For Orphan Drug Designation

8.4 Verification Of Orphan Drug Status & Resident Agent For Foreign Sponsor

8.5 Timing Of Requests For Orphan Drug Designation & Designation Of Already Approved Drugs

8.6 Deficiency Letters And Granting Orphan Drug Designation

8.7 Refusal To Grant Orphan Drug Designation

8.8 Amendment & Change In Ownership To Orphan Drug Designation

8.9 Publication & Revocation Of Orphan Drug Designations

8.10 Annual Reports Of Holder Of Orphan Drug Designation

8.11 Scope & FDA Recognition Of Orphan Drug Exclusive Approval

8.12 Protocols for Investigations & Availability of Information



EMA Regulations for Clinical Trials of Orphan Designated Drugs
9.1 Committee for Orphan Medicinal Products

9.2 How to Apply for Orphan Designation in Europe

9.3 Marketing Authorization & Market Exclusivity

9.4 Transferring An Orphan Designation To Another Sponsor

9.5 Mandatory Submission Of Annual Report On Development

9.6 Incentives For Micro, Small And Medium-Sized Enterprises

9.7 Fee Reductions For Designated Orphan Medicinal Products

9.8 Procedure for Orphan Designation & Incentives for R&D



Asian Regulations for Clinical Trials of Orphan Designated Drugs
10.1 Taiwan Rare Disease and Orphan Drug Act

10.2 Japan Orphan Drug Regulation





Global Orphan Drug Clinical Pipeline by Company, Indication & Phase
11.1 Unknown

11.2 Research

11.3 Preclinical

11.4 Clinical

11.5 Phase-I

11.6 Phase-I/II

11.7 Phase-II

11.8 Phase-II/III

11.9 Phase-III

11.10 Preregistration

11.11 Registered



Marketed Global Orphan Drug Clinical Insight by Company & Indication


Competitive Landscape
13.1 AOP Orphan

13.2 Agenus

13.3 Alexion

13.4 Bristol Myers Squibb

13.5 Biogen Idec

13.6 Celgene

13.7 Eli Lilly

13.8 Genethon

13.9 Genzyme Corporation

13.10 Glaxosmithkline

13.11 Merck

13.12 Novartis Pharmaceuticals

13.13 Orphan Europe

13.14 Pfizer

13.15 Prosensa

13.16 Rare Disease Therapeutics

13.17 Roche

13.18 Sanofi

13.19 Shire

13.20 Teva Pharmaceutical

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Sharma
rajesh@pnspharma.com
PNS Pharma
New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Orphan Drug Pipeline & Regulatory Insight 2025 here

News-ID: 1453434 • Views: 101

More Releases from PNS Pharma

Global Cancer Vaccine Market & Clinical Trial Insight 2025
Recent published report “Global Cancer Vaccine Market & Clinical Trial Insight 2025“ by PNS Pharma highlights on going developments in the field of cancer vaccine market research and clinical trials. currently there are more than 15 cancer vaccines commercially available in the market and close to 370 are in clinical Trial or pipeline. Most of the vaccines in development phases are for the treatment of Breast cancer and
Global Orphan Drug Pipeline & Regulatory Insight 2025
” Global Orphan Drug Pipeline & Regulatory Insight 2025” Report Highlights: Global Orphan Drug Market Overview: US$ 260 Billion Opportunity Global Orphan Drug market by Segment Regulatory Landscape: USA, Europe & Asia Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia Global Orphan Drug Clinical Pipeline Insight: 973 Drugs Marketed Orphan Drug Clinical Insight: 366 Drugs Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Orphan-Drug-Pipeline-%26-Regulatory-Insight-2025 Report TOC Orphan Drugs: Regimens For Rare Diseases Drivers of Orphan Drug Commercialization 2.1 Cost
Global Cancer Vaccine Market & Clinical Trial Insight 2025
Global Cancer Vaccine Market & Clinical Trial Insight 2025″ Report Highlight: Global Cancer Vaccine Market Opportunity: US$ 15 Billion Opportunity Personalized Cancer Vaccine: The Next growth Frontier Global Cancer Vaccine Clinical insight by Indication & Phase of Development Global Cancer Vaccine Pipeline: 369 Cancer Vaccines Marketed Cancer Vaccines: 17 Cancer Vaccines Maximum Vaccines in Pipeline for Brain & Breast Cancer: 43 Cancer Vaccines Regulatory Landscape Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Cancer-Vaccine-Market-%26-Clinical-Trial-Insight-2025 Introduction to Cancer Vaccines Mechanism
Global Orphan Drug Market Offers USD 250 Billion Opportunity By 2025
Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Orphan-Drug-Pipeline-%26-Regulatory-Insight-2025 Total sales of orphan designated drugs is expected to surpass US$ 250 Billion by 2025 as per recent report “Global Orphan Drug Pipeline & Regulatory Insight 2025” published by PNS Pharma. The strong clinical pipeline and availability of more than 350 orphan designated drugs in the market will drive the global orphan drug market in coming years. "Global Orphan Drug Pipeline & Regulatory Insight 2025" Report Highlights: • Global Orphan Drug

All 5 Releases


More Releases for Orphan

Global Orphan Drug Pipeline & Regulatory Insight 2025
” Global Orphan Drug Pipeline & Regulatory Insight 2025” Report Highlights: Global Orphan Drug Market Overview: US$ 260 Billion Opportunity Global Orphan Drug market by Segment Regulatory Landscape: USA, Europe & Asia Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia Global Orphan Drug Clinical Pipeline Insight: 973 Drugs Marketed Orphan Drug Clinical Insight: 366 Drugs Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Orphan-Drug-Pipeline-%26-Regulatory-Insight-2025 Report TOC Orphan Drugs: Regimens For Rare Diseases Drivers of Orphan Drug Commercialization 2.1 Cost
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the
Global Orphan Drug Clinical Pipeline Insight 2022
“Global Orphan Drug Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan
Global Orphan Drugs Market Report: 2016 Edition
A rare disease is the one that occurs uncommonly or rarely in the general population. However, there exists no clear definition for categorizing “rare diseases” and is usually defined on the basis of the prevalence, and some other factors including the severity of disease and availability of treatment options. Rare diseases are often serious, chronic and progressive. Orphan drugs are medicinal products intended for the diagnosis, prevention or treatment of rare